Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394652 | 0.83 | TSHR (0.31) | — | |
| SCHEMBL11357992 | 0.78 | GABRA1 (0.38) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5354591 | 0.73 | GABRA1 (0.34) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL21211716 | 0.73 | POLB (0.38) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29636322 | 0.73 | GABRA1 (0.54) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL285281 | 0.73 | GABRA1 (0.54) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5352813 | 0.73 | GABRA1 (0.34) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20780625 | 0.73 | GABRA1 (0.34) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5354598 | 0.73 | GABRA1 (0.34) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL392803 | 0.73 | CYP1A2 (0.34) | GABRA1GABRB2CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030003358-A1 | Thermal runaway inhibitors | ENERGY, UNITED STATES, DEPARTMENT OF | 2003-01-02 | — | — | US | claimed |
| CN-113387055-B | Film, method for producing film, and bag | 住友化学株式会社 | 2024-06-07 | — | — | CN | disclosed |
| CN-112724302-B | Ethylene-alpha-olefin copolymer, process for producing the same, ethylene resin composition, and film | 住友化学株式会社 | 2023-10-31 | — | — | CN | disclosed |
| US-11643533-B2 | Film, method of producing film, and bag | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-05-09 | — | — | US | disclosed |
| CN-112638997-B | Film and packaging container | 住友化学株式会社 | 2023-04-28 | — | — | CN | disclosed |
| CN-110352213-B | Film | 住友化学株式会社 | 2022-09-09 | — | — | CN | disclosed |
| US-11149102-B2 | Film | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20210284829-A1 | FILM, METHOD OF PRODUCING FILM, AND BAG | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3878896-A1 | FILM, METHOD OF PRODUCING FILM, AND BAG | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2021-09-15 | — | — | EP | disclosed |
| CN-113387055-A | Film, method for producing film, and bag | 住友化学株式会社 | 2021-09-14 | — | — | CN | disclosed |
| US-20030069127-A1 | Modified particle,support, catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMTED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1300425-A2 | Catalyst component for addition polymerization, process for producing said catalyst and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-20030060579-A1 | Catalyst component for addition polymerization, process for producing catalyst for addition polymerization and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1275662-A1 | MODIFIED PARTICLE, SUPPORT, CATALYST COMPONENT FOR ADDITION POLYMERIZATION, CATALYST FOR ADDITION POLYMERIZATION, AND PROCESS FOR PRODUCING ADDITION POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-20020143124-A1 | Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-03 | — | — | US | disclosed |
| US-20020013433-A1 | Transition metal compound, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-31 | — | — | US | disclosed |
| US-20010053832-A1 | Olefin polymerization catalyst and process for producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-12-20 | — | — | US | disclosed |
| EP-1153938-A1 | CATALYST FOR STEREOREGULAR POLYMERIZATION OF ALPHA-OLEFIN AND PROCESS FOR PRODUCING STEREOREGULAR ALPHA-OLEFIN POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-11-14 | — | — | EP | disclosed |
| EP-1134234-A1 | Olefin polymerization catalyst and process for producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-19 | — | — | EP | disclosed |
| EP-1081167-A1 | Olefin polymerization catalyst and process for producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013433-A1 | Transition metal compound, catalyst for addition polymerization, and process for producing addition polymer | ASH2L, ARL1, AS3MT | GABRA1 1971/4885GABRB2 2903/4885CYP1A2 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.